Stuart L Cohen1,2, Eugenia Gianos3, Mathew A Barish1, Saurav Chatterjee3,4, Nina Kohn2, Martin Lesser2,4, Dimitrios Giannis2,4, Kevin Coppa5, Jamie S Hirsch2,4,5, Thomas G McGinn2,4, Mark E Goldin2,4, Alex C Spyropoulos2,4. 1. Department of Radiology, Northwell Health, Manhasset, New York, United States. 2. Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States. 3. Department of Cardiology, Northwell Health, Manhasset, New York, United States. 4. Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, United States. 5. Department of Information Services, Northwell Health, New Hyde Park, New York, United States.
Abstract
BACKGROUND: We aimed to identify the prevalence and predictors of venous thromboembolism (VTE) or mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. METHODS: A retrospective cohort study of hospitalized adult patients admitted to an integrated health care network in the New York metropolitan region between March 1, 2020 and April 27, 2020. The final analysis included 9,407 patients with an overall VTE rate of 2.9% (2.4% in the medical ward and 4.9% in the intensive care unit [ICU]) and a VTE or mortality rate of 26.1%. Most patients received prophylactic-dose thromboprophylaxis. Multivariable analysis showed significantly reduced VTE or mortality with Black race, history of hypertension, angiotensin converting enzyme/angiotensin receptor blocker use, and initial prophylactic anticoagulation. It also showed significantly increased VTE or mortality with age 60 years or greater, Charlson Comorbidity Index (CCI) of 3 or greater, patients on Medicare, history of heart failure, history of cerebrovascular disease, body mass index greater than 35, steroid use, antirheumatologic medication use, hydroxychloroquine use, maximum D-dimer four times or greater than the upper limit of normal (ULN), ICU level of care, increasing creatinine, and decreasing platelet counts. CONCLUSION: In our large cohort of hospitalized COVID-19 patients, the overall in-hospital VTE rate was 2.9% (4.9% in the ICU) and a VTE or mortality rate of 26.1%. Key predictors of VTE or mortality included advanced age, increasing CCI, history of cardiovascular disease, ICU level of care, and elevated maximum D-dimer with a cutoff at least four times the ULN. Use of prophylactic-dose anticoagulation but not treatment-dose anticoagulation was associated with reduced VTE or mortality. Thieme. All rights reserved.
BACKGROUND: We aimed to identify the prevalence and predictors of venous thromboembolism (VTE) or mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. METHODS: A retrospective cohort study of hospitalized adult patients admitted to an integrated health care network in the New York metropolitan region between March 1, 2020 and April 27, 2020. The final analysis included 9,407 patients with an overall VTE rate of 2.9% (2.4% in the medical ward and 4.9% in the intensive care unit [ICU]) and a VTE or mortality rate of 26.1%. Most patients received prophylactic-dose thromboprophylaxis. Multivariable analysis showed significantly reduced VTE or mortality with Black race, history of hypertension, angiotensin converting enzyme/angiotensin receptor blocker use, and initial prophylactic anticoagulation. It also showed significantly increased VTE or mortality with age 60 years or greater, Charlson Comorbidity Index (CCI) of 3 or greater, patients on Medicare, history of heart failure, history of cerebrovascular disease, body mass index greater than 35, steroid use, antirheumatologic medication use, hydroxychloroquine use, maximum D-dimer four times or greater than the upper limit of normal (ULN), ICU level of care, increasing creatinine, and decreasing platelet counts. CONCLUSION: In our large cohort of hospitalized COVID-19 patients, the overall in-hospital VTE rate was 2.9% (4.9% in the ICU) and a VTE or mortality rate of 26.1%. Key predictors of VTE or mortality included advanced age, increasing CCI, history of cardiovascular disease, ICU level of care, and elevated maximum D-dimer with a cutoff at least four times the ULN. Use of prophylactic-dose anticoagulation but not treatment-dose anticoagulation was associated with reduced VTE or mortality. Thieme. All rights reserved.
Authors: Tobias Tritschler; Marie-Eve Mathieu; Leslie Skeith; Marc Rodger; Saskia Middeldorp; Timothy Brighton; Per Morten Sandset; Susan R Kahn; Derek C Angus; Marc Blondon; Marc J Bonten; Marco Cattaneo; Mary Cushman; Lennie P G Derde; Maria T DeSancho; Jean-Luc Diehl; Ewan Goligher; Bernd Jilma; Peter Jüni; Patrick R Lawler; Marco Marietta; John C Marshall; Colin McArthur; Carlos Henrique Miranda; Tristan Mirault; Nuccia Morici; Usha Perepu; Christian Schörgenhofer; Michelle Sholzberg; Alex C Spyropoulos; Steve A Webb; Ryan Zarychanski; Stéphane Zuily; Grégoire Le Gal Journal: J Thromb Haemost Date: 2020-10-01 Impact factor: 5.824
Authors: Ishan Paranjpe; Valentin Fuster; Anuradha Lala; Adam J Russak; Benjamin S Glicksberg; Matthew A Levin; Alexander W Charney; Jagat Narula; Zahi A Fayad; Emilia Bagiella; Shan Zhao; Girish N Nadkarni Journal: J Am Coll Cardiol Date: 2020-05-06 Impact factor: 24.094
Authors: Sharon E Fox; Aibek Akmatbekov; Jack L Harbert; Guang Li; J Quincy Brown; Richard S Vander Heide Journal: Lancet Respir Med Date: 2020-05-27 Impact factor: 30.700
Authors: Dominic Wichmann; Jan-Peter Sperhake; Marc Lütgehetmann; Stefan Steurer; Carolin Edler; Axel Heinemann; Fabian Heinrich; Herbert Mushumba; Inga Kniep; Ann Sophie Schröder; Christoph Burdelski; Geraldine de Heer; Axel Nierhaus; Daniel Frings; Susanne Pfefferle; Heinrich Becker; Hanns Bredereke-Wiedling; Andreas de Weerth; Hans-Richard Paschen; Sara Sheikhzadeh-Eggers; Axel Stang; Stefan Schmiedel; Carsten Bokemeyer; Marylyn M Addo; Martin Aepfelbacher; Klaus Püschel; Stefan Kluge Journal: Ann Intern Med Date: 2020-05-06 Impact factor: 25.391
Authors: L Silvia Muñoz-Price; Ann B Nattinger; Frida Rivera; Ryan Hanson; Cameron G Gmehlin; Adriana Perez; Siddhartha Singh; Blake W Buchan; Nathan A Ledeboer; Liliana E Pezzin Journal: JAMA Netw Open Date: 2020-09-01
Authors: Gary E Raskob; Alex C Spyropoulos; Theodore E Spiro; Wentao Lu; Zhong Yuan; Bennett Levitan; Eunyoung Suh; Elliot S Barnathan Journal: J Am Heart Assoc Date: 2021-11-10 Impact factor: 5.501
Authors: Joby J Thoppil; D Mark Courtney; Samuel McDonald; Christopher Kabrhel; Kristen E Nordenholz; Carlos A Camargo; Jeffrey A Kline Journal: J Emerg Med Date: 2022-01-17 Impact factor: 1.473
Authors: Mark Goldin; Stephanie K Lin; Nina Kohn; Michael Qiu; Stuart L Cohen; Matthew A Barish; Eugenia Gianos; Anise Diaz; Safiya Richardson; Dimitrios Giannis; Saurav Chatterjee; Kevin Coppa; Jamie S Hirsch; Sam Ngu; Sheila Firoozan; Thomas McGinn; Alex C Spyropoulos Journal: J Thromb Thrombolysis Date: 2021-06-19 Impact factor: 5.221